Trial Profile

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 4956 (Primary) ; Saruparib
Indications Adenocarcinoma; Breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors AstraZeneca

27 Mar 2026 Planned End Date changed from 10 Jul 2029 to 29 Mar 2030.
27 Mar 2026 Planned primary completion date changed from 10 Jul 2029 to 29 Mar 2030.
27 Mar 2026 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com